2018
TCT-624 A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent: Subgroup Analysis of the TARGET All Comers Trial
Lansky A, Wijns W, Xu B, Kelbaek H, van Royen N, Zheng M, Artus-Jacenko L, Knaapen P, Slagboom T, Vlachojannis G, Arkenbout K, Holmvang L, Janssens L, Ochala A, Brugaletta S, Bruder O, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Johnson T, Thiele H, Baumbach A. TCT-624 A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent: Subgroup Analysis of the TARGET All Comers Trial. Journal Of The American College Of Cardiology 2018, 72: b249-b250. DOI: 10.1016/j.jacc.2018.08.1826.Peer-Reviewed Original Research
2000
Randomized Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenoses
Lansky A, Roubin G, O’Shaughnessy C, Moore P, Dean L, Raizner A, Safian R, Zidar J, Kerr J, Popma J, Mehran R, Kuntz R, Leon M. Randomized Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenoses. Circulation 2000, 102: 1364-1368. PMID: 10993853, DOI: 10.1161/01.cir.102.12.1364.Peer-Reviewed Original ResearchConceptsCoronary stenosisPalmaz-SchatzElective treatmentDe novo native coronary stenosisStent minimal lumen diameterMultivariate logistic regression analysisPrimary end pointTarget lesion revascularizationFree survival rateStent thrombosis ratesLong-term followNative coronary stenosisMinimal lumen diameterLogistic regression analysisPalmaz-Schatz stentsBalloon angioplasty proceduresRestenosis frequencyAngiographic restenosisLesion revascularizationProspective multicenterTLR rateFree survivalAcute treatmentConsecutive patientsDiabetes mellitus